News | July 02, 2022
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
It´s the first trial to demonstrate the benefits of dual pathway inhibition
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Alopecia areata usually presents as a few small bald patches in the head
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Subscribe To Our Newsletter & Stay Updated
